Comparison · NCT00404924-36977d39
Vandetanib 300 mg vs Placebo: Disease Control Rate (DCR)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Vandetanib 300 mg vs Placebo: Disease Control Rate (DCR). Trial comparisons, record NCT00404924-36977d39. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00404924-36977d39
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.306 | 0.271 | 0.344 | wilson | |
| Risk in group 2 | 0.156 | 0.12 | 0.201 | wilson | |
| Risk difference, group 1 minus group 2 | 0.15 | 0.093 | 0.202 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.96 | 1.47 | 2.61 | log | |
| Odds ratio, group 1 over group 2 | 2.38 | 1.68 | 3.39 | log | |
| Number needed to treat, for one more participant with the outcome on Vandetanib 300 mg than on Placebo | 6.67 | 4.95 | 10.7 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Vandetanib 300 mg | vandetanib (300 mg daily) plus best supportive care | 189 | 617 | OG000 |
| Group 2 | Placebo | Placebo plus best supportive care | 48 | 307 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Disease Control Rate (DCR)
- Description
Disease control rate is defined as the number of patients who achieved disease control at 8 weeks following randomisation. Disease control at 8 weeks is defined as a best objective response of complete response (CR), partial response (PR) or stable disease (SD) \>= 8 weeks
- Time frame
- RECIST tumour assessments carried out every 8 weeks from randomisation until objective disease progression
- Population
Source ClinicalTrials.gov
Trial
- Title
- ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
- NCT number
- NCT00404924
- Phases
- PHASE3
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- ZD6474 (vandetanib), Best Supportive Care
- Lead sponsor
- Genzyme, a Sanofi Company
- Results first posted
- 2012-03-26
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00404924?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00404924-36977d39